BR9809703A - Acilanilidas (hetero) ciclicamente substituìdas, não esteroidais, com eficácia gestagênica e androgênica mista - Google Patents

Acilanilidas (hetero) ciclicamente substituìdas, não esteroidais, com eficácia gestagênica e androgênica mista

Info

Publication number
BR9809703A
BR9809703A BR9809703-2A BR9809703A BR9809703A BR 9809703 A BR9809703 A BR 9809703A BR 9809703 A BR9809703 A BR 9809703A BR 9809703 A BR9809703 A BR 9809703A
Authority
BR
Brazil
Prior art keywords
group
gestagenic
treatment
alkyl group
addition
Prior art date
Application number
BR9809703-2A
Other languages
English (en)
Inventor
Manfred Lahmann
Klaus Schoellkopf
Peter Strehlke
Nikolaus Heinrich
Karl-Heinrich Fritzemeier
Hans-Peter Muhn
Rolf Krattenmacher
Original Assignee
Schering Aktiengellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7831567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9809703(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengellschaft filed Critical Schering Aktiengellschaft
Publication of BR9809703A publication Critical patent/BR9809703A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Patente de Invenção:<B>"ACILANILIDAS (HETERO) CICLICAMENTE SUBSTITUìDAS, NãO ESTEROIDAIS, COM EFICáCIA GESTAGêNICA E ANDROGêNICA MISTA"<D>. A presente invenção descreve agentes gestagênicos não esteroidais da fórmula geral (I), na qual R^ 1^ e R^ 2^ são iguais ou diferentes e representam um átomo de hidrogênio, um grupo C~ 1~-C~ 5~ alquila ou um átomo de halogênio, além disso, em conjunto com o átomo de carbono da cadeia, representa um anel com, no total, 3-7 membros, R^ 3^ representa um grupo C~ 1~-C~ 5~- alquila ou um grupo C~ 1~-C~ 5~- alquila parcialmente ou completamente fluorado, A representa um anel aromático mono- ou bicíclico eventualmente substituído, representa um grupo éster - COOR^ 4^, representa um grupo alquenila - CR^ 5^=CR^ 6^R^ 7^, representa um grupo alquinila - C-<154>CR^ 6^R^ 7^, representa um grupo C~ 1~-C~ 5~- alquila parcialmente ou completamente fluorado; B representa um grupo carbonila ou um grupo CH~ 2~ e Ar representa adicionalmente um sistema de anel, escolhido das fórmulas parciais gerais (2-11), além disso, para o caso em que B, na fórmula geral (I), represente um grupo -CH~ 2~-, Ar adicionalmente representa um radical fenila da fórmula parcial geral (12). Os novos compostos mostram uma afinidade muito forte com relação ao receptor gestagênico. Eles podem ser utilizados isoladamente ou em combinação com estrogênios, em preparados para a contracepção. Além disso, eles podem servir para o tratamento da endometriose. Em conjunto com estrogênios, eles também podem ser utilizados em preparados para o tratamento de distúrbios ginecológicos para o tratamento de reclamações pré-menstruais e para a terapia de substituição. Com base na eficácia androgênica, eles também podem servir para o controle de fertilidade masculino, HRT masculina e terapia com hormónios e para o tratamento de quadros de doenças andrológicas.
BR9809703-2A 1997-05-30 1998-06-02 Acilanilidas (hetero) ciclicamente substituìdas, não esteroidais, com eficácia gestagênica e androgênica mista BR9809703A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19723722A DE19723722A1 (de) 1997-05-30 1997-05-30 Nichtsteroidale Gestagene
PCT/EP1998/003242 WO1998054159A1 (de) 1997-05-30 1998-06-02 Nichtsteroidale (hetero)zyklisch-substituierte acylanilide mit gemischter gestagener und androgener wirksamkeit

Publications (1)

Publication Number Publication Date
BR9809703A true BR9809703A (pt) 2000-07-11

Family

ID=7831567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809703-2A BR9809703A (pt) 1997-05-30 1998-06-02 Acilanilidas (hetero) ciclicamente substituìdas, não esteroidais, com eficácia gestagênica e androgênica mista

Country Status (30)

Country Link
EP (1) EP0986545B1 (pt)
JP (1) JP2002502385A (pt)
KR (1) KR100536870B1 (pt)
CN (1) CN100445272C (pt)
AR (1) AR011480A1 (pt)
AT (1) ATE286035T1 (pt)
AU (1) AU747083C (pt)
BG (1) BG64212B1 (pt)
BR (1) BR9809703A (pt)
CA (1) CA2305458C (pt)
CZ (1) CZ296377B6 (pt)
DE (2) DE19723722A1 (pt)
EA (1) EA004306B1 (pt)
EE (1) EE04492B1 (pt)
ES (1) ES2234121T3 (pt)
HR (1) HRP980289B1 (pt)
HU (1) HUP0002126A3 (pt)
ID (1) ID23499A (pt)
IL (2) IL133195A0 (pt)
IS (1) IS2498B (pt)
NO (1) NO325076B1 (pt)
NZ (1) NZ501359A (pt)
PL (1) PL197887B1 (pt)
PT (1) PT986545E (pt)
SK (1) SK284943B6 (pt)
TR (1) TR199902924T2 (pt)
TW (1) TW577882B (pt)
UA (1) UA64752C2 (pt)
WO (1) WO1998054159A1 (pt)
ZA (1) ZA984655B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
DE10346940B3 (de) * 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
EP1373888A2 (en) * 2000-12-28 2004-01-02 Schering Aktiengesellschaft Method for screening for progesterone receptor isoform-specific ligands
EP1467982B8 (en) * 2002-01-14 2007-04-11 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
DK1482925T3 (da) * 2002-03-11 2007-05-14 Bayer Schering Pharma Ag 5- (2-hydroxy-3 -'1 - (3-trifluormethylphenyl) cyclopropylpropionylamino) phtalid og relaterede forbindelser med progesteronreceptormoducerende aktivitet til anvendelse i fertilitetskontrol og hormonerstatningsterapi
EP1344776A1 (en) * 2002-03-11 2003-09-17 Schering Aktiengesellschaft 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4324480B2 (ja) 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
DE10215316C1 (de) * 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
NZ538932A (en) 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
JP2006518328A (ja) * 2002-10-15 2006-08-10 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 複素環選択的アンドロゲン受容体調節剤及びその使用方法
DE10261874A1 (de) * 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
EP1583745A1 (en) 2003-01-03 2005-10-12 Boehringer Ingelheim Pharmaceuticals Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
US20040224992A1 (en) * 2003-02-27 2004-11-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2531060A1 (en) * 2003-07-01 2005-01-13 Schering Aktiengesellschaft Heterocyclically-substitued pentanol derivatives, process for their production and their use as anti-inflammatory agents
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
JP4468369B2 (ja) 2003-10-16 2010-05-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ある種のトリフルオロメチル置換アルコールの立体選択的合成
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
PE20060776A1 (es) 2004-12-27 2006-09-26 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas
JP5281291B2 (ja) 2005-01-10 2013-09-04 グラクソ グループ リミテッド 新規化合物
WO2006083030A1 (ja) * 2005-02-04 2006-08-10 Ajinomoto Co., Inc. 脂肪酸の製造方法および脂肪酸の塩結晶
UY29439A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
DE102005017326A1 (de) * 2005-04-14 2007-03-29 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
DE102005030293A1 (de) * 2005-06-24 2007-01-04 Schering Ag Verwendung von nichtsteroidale Progesteronrezeptor-Modulatoren
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1963287A1 (en) 2005-12-09 2008-09-03 F.Hoffmann-La Roche Ag Glucocorticoid receptor modulators as antiinflammatory agents
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
MX2009005264A (es) 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
UY30815A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroidales del receptor de progesterona
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
JP5090773B2 (ja) * 2006-12-26 2012-12-05 国立大学法人東京工業大学 光学活性含フッ素カルボニル−エン生成物の製造方法
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) * 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
DK2300472T3 (da) 2008-06-06 2012-04-10 Boehringer Ingelheim Int Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP2411517A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
JP5795643B2 (ja) 2010-10-21 2015-10-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
WO2012052459A1 (en) 2010-10-21 2012-04-26 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
US9399637B2 (en) 2014-03-28 2016-07-26 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3569228A1 (en) * 2018-05-17 2019-11-20 Association pour la recherche à l'IGBMC (ARI) Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
WO2019099311A1 (en) 2017-11-19 2019-05-23 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3740468B1 (en) 2018-01-20 2025-12-31 Sunshine Lake Pharma Co., Ltd. Substituted Aminopyrimidine Compounds and Methods of Use
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections
KR20230024328A (ko) * 2020-06-12 2023-02-20 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
CN114605308B (zh) * 2022-03-18 2023-12-19 阜新孚隆宝医药科技有限公司 一种帕罗韦德的氮杂双环医药中间体的制备方法及中间体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS5789048A (en) * 1980-11-20 1982-06-03 Nat Jutaku Kenzai Independent pilar with cover
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
JPH07508987A (ja) * 1992-07-01 1995-10-05 オーソ・フアーマシユーチカル・コーポレーシヨン １−アリールスルホニル，アリールカルボニルおよび１−アリールホスホニル−３−フェニル−１，４，５，６−テトラヒドロピリダジン

Also Published As

Publication number Publication date
CA2305458A1 (en) 1998-12-03
EP0986545A1 (de) 2000-03-22
IS2498B (is) 2009-02-15
IS5241A (is) 1999-11-09
PL337088A1 (en) 2000-07-31
IL133195A0 (en) 2001-03-19
KR100536870B1 (ko) 2005-12-16
PL197887B1 (pl) 2008-05-30
SK284943B6 (sk) 2006-02-02
EP0986545B1 (de) 2004-12-29
HRP980289A2 (en) 1999-02-28
EA004306B1 (ru) 2004-02-26
PT986545E (pt) 2005-04-29
NO995845L (no) 2000-01-27
CZ296377B6 (cs) 2006-03-15
JP2002502385A (ja) 2002-01-22
AU747083B2 (en) 2002-05-09
DE59812452D1 (de) 2005-02-03
CZ425799A3 (cs) 2000-04-12
NZ501359A (en) 2001-11-30
ATE286035T1 (de) 2005-01-15
AU8021198A (en) 1998-12-30
CA2305458C (en) 2007-05-01
AR011480A1 (es) 2000-08-16
EE9900548A (et) 2000-06-15
BG103903A (en) 2000-04-28
EA199900989A1 (ru) 2000-08-28
NO325076B1 (no) 2008-01-28
NO995845D0 (no) 1999-11-29
UA64752C2 (uk) 2004-03-15
DE19723722A1 (de) 1998-12-10
SK160999A3 (en) 2000-07-11
CN100445272C (zh) 2008-12-24
IL133195A (en) 2007-07-24
HUP0002126A3 (en) 2002-12-28
CN1258286A (zh) 2000-06-28
EE04492B1 (et) 2005-06-15
TW577882B (en) 2004-03-01
WO1998054159A1 (de) 1998-12-03
HUP0002126A2 (hu) 2001-06-28
KR20010013123A (ko) 2001-02-26
ES2234121T3 (es) 2005-06-16
ID23499A (id) 2000-04-27
BG64212B1 (bg) 2004-05-31
ZA984655B (en) 1999-03-16
AU747083C (en) 2004-01-29
TR199902924T2 (xx) 2000-02-21
HRP980289B1 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
EA199900989A1 (ru) Нестероидные (гетеро)циклически замещенные ациланилиды, обладающие смешанным гестагенным и андрогенным действием
BR0112364A (pt) Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios
CY1105957T1 (el) Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης
CY1108093T1 (el) Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη
PE55998A1 (es) Derivados 19-nor-pregneno substituidos
BR0307524A (pt) Composição farmacêutica para inibidores de protease viral de hepatite c
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
BR0205684A (pt) Compostos cìclicos fundidos e seu uso medicinal
DK0398460T3 (da) Anvendelse af dihydrospirorenon som anti-androgen
NO994091L (no) Medisinsk preparat inneholdende en lipofilisk inertgass
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
DK1112067T3 (da) Anvendelse af acetylcholinesteraseinhibitorer til fremstilling af farmaceutiske præparater til behandling af funktionelle og/eller organiske smertesyndromer
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
ATE359786T1 (de) Camptothecin derivate
CY1104981T1 (el) Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων
HUP9901288A2 (hu) LHRH-analógokat és antiösztrogéneket tartalmazó kombinációs gyógyszerkészítmények nőgyógyászati zavarok kezelésére
AR004502A1 (es) Una asociacion trisecuencial hormonal, estroprogestativa, su utilizacion y un procedimiento para su preparacion
ES2164400T3 (es) Esteroides con actividad anticonceptiva y antiosteoporotica.
BR0109022A (pt) Método de preparação de citalopram e sua composição farmacêutica
BR0213291A (pt) Composição e método para tratamento de diabetes
ATE277913T1 (de) Bisarylderivate mit fsh rezeptor modulierender aktivität
EA200300756A1 (ru) Андрогенные 7-замещенные-11-галогенированные стероиды
ZA200500217B (en) 9-Alpha-substituted estratienes as selectively active estrogen
DE60111553D1 (de) Hexahydropyrazino[1&#39;2&#39;:1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
DE60209248D1 (de) Verwendung von (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)-estra-4,9-dien-3-on zur behandlung von schweren depressionen

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A E 13A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.